Related Experiment Videos
Antiproliferative monoclonal antibodies: detection and initial characterization
Journal of Immunology (Baltimore, Md. : 1950)
|September 1, 1985
Summary
Two novel monoclonal antibodies (MAB) were developed to inhibit cancer cell proliferation. These antibodies target specific cell surface markers, offering potential for targeted cancer therapies.
Area of Science:
- Immunology
- Cell Biology
- Oncology
Background:
- Monoclonal antibodies (MAB) are crucial tools in understanding cellular functions.
- Targeting cell proliferation is a key strategy in cancer therapy.
Purpose of the Study:
- To develop and characterize novel monoclonal antibodies that inhibit in vitro cellular proliferation.
- To investigate the mechanisms and targets of these inhibitory antibodies.
Main Methods:
- Hybridoma technology was used to generate MAB against human B lymphoma cells.
- A colorimetric proliferation assay quantified cellular activity.
- Immunofluorescence and immunoprecipitation identified antibody targets.
Main Results:
- Two MABs, RBC4 (IgM) and RBG5 (IgG1), were identified that inhibit cellular proliferation.
- RBC4 targets the transferrin receptor, while RBG5 targets a different surface determinant.
- Both MABs inhibited proliferation of activated human peripheral blood lymphocytes and various cell lines.
Conclusions:
- RBC4 and RBG5 are potent inhibitors of cellular proliferation with distinct mechanisms.
- These MABs demonstrate potential as therapeutic agents for B cell malignancies and other proliferative disorders.